Eric Arnoult, PhD, has extensive work experience in the scientific and pharmaceutical industries. Eric is currently a Sr Application Scientist Manager at OpenEye, Cadence Molecular Sciences since July 2023. Prior to this, they worked at Ferring Pharmaceuticals as an Associate Scientific Director from January 2022 to May 2023.
Before that, Eric was at GSK, where they served as a Scientific Leader from November 2019 to January 2022 and as an Investigator, Molecular Design from October 2017 to November 2019.
Eric also has experience working at Janssen Inc. as a Senior Scientist from March 2014 to September 2017, at Janssen-Cilag, S.A. as a Senior Scientist from January 2005 to February 2014, and at Sanofi-Synthelabo as a Scientist from March 2004 to January 2005.
Eric started their career as a PhD student at VIRSOL from 2000 to 2003. With a strong background in scientific research and leadership, Eric has demonstrated a consistent track record of contributing to various organizations in the pharmaceutical industry.
Eric Arnoult, PhD, completed their education in chemistry and computer-aided drug design at the Université d'Orléans. From 2000 to 2004, they pursued their PhD in this field. Prior to that, they obtained a Master's degree from the same university in the subjects of molecular biology, biophysics, and biochemistry. This education history suggests that Dr. Arnoult has a strong foundation in the scientific disciplines related to chemistry, biology, and computer-aided drug design.
This person is not in any offices
OpenEye, Cadence Molecular Sciences
OpenEye Scientific is an industry leader in computational molecular design based on decades of delivering rapid, robust, and scalable software, toolkits, and technology and design services across the drug discovery process. Our scientific approach has focused on visualizing and analyzing the shape and electrostatics of molecular 3D structures to inform and guide the advancement of pharmaceuticals and biotechnology. OpenEye recently integrated its applications and toolkits into Orion, the only cloud-native, fully integrated molecular design platform. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. Founded in 1997, OpenEye is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts; Cologne, Germany; and Tokyo, Japan. For more information, go to http://www.eyesopen.com.
Employees
51-200